Comparison between Fibroscan and Hepatus for Detecting NAFLD in Patients with Metabolic Dysregulation.

Background The clinical application of the innovative instantaneous elasticity technology is currently in the evaluation stage. This study aimed to compare the detection performance of Fibroscan and Hepatus in detecting nonalcoholic fatty liver disease (NAFLD) among patients with metabolic dysregulation. Methods This prospective study was conducted between January 2021 and April 2021 with 149 patients enrolled. Clinical data were collected, and all patients underwent both Fibroscan and Hepatus to determine liver stiffness measurement (LSM) and attenuation parameters. Pearson correlation analysis and scatter diagram were used to analyze the correlation, while a paired t-test was used to compare the differences between the detected values from the two machines. Receiver operating characteristic curves (ROC) were constructed to compare the diagnostic cut-off for Hepatic Steatosis Index (HSI)-based NAFLD. Results The detection success rate of Hepatus (100.0%) was higher than that of Fibroscan (96.0%). And we found that the LSM (r = 0.663, P<0.001) and attenuation parameters (r = 0.778, P<0.001) obtained by Fibroscan and Hepatus were significantly correlated. Hepatus tended to produce a higher LSM value (Hepatus vs. Fibroscan: 6.04 vs. 5.66 kPa, P=0.016), but a lower attenuation parameter value than Fibroscan (Hepatus vs. Fibroscan: 264 vs. 277 dB/m, P<0.001). The area under the ROC curve for detecting HSI-based NAFLD was 0.811 for Fibroscan and 0.832 for Hepatus. Conclusion Measurements obtained by Fibroscan and Hepatus are highly correlated, and the diagnostic value of the two TE devices is comparable in detecting HSI-based NAFLD. [ABSTRACT FROM AUTHOR]